NCT00600587View on ClinicalTrials.gov

Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

neoadjuvant erlotinib therapy

150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.

DRUG

neoadjuvant gemcitabine/carboplatin therapy

3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.

Trial Locations (1)

510080

Guangdong General Hospital, Guangzhou

All Listed Sponsors
lead

Guangdong Provincial People's Hospital

OTHER

NCT00600587 - Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC) | Biotech Hunter | Biotech Hunter